Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

696.62 -6.64 (-0.94%)
Streaming Delayed Price Updated: 1:21 PM EST, Dec 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
58 59 Next >
News headline image
Eli Lilly, AbbVie, Bristol Myers, Regeneron, And Other Pharma Companies Slide As Donald Trump Confirms Tariffs On Pharma Companies ↗
Even as Donald Trump paused the reciprocal tariffs for 90 days, he later confirmed that pharmaceutical companies would face tariffs. 
Via Benzinga
Topics Government World Trade
News headline image
Pharma Industry Faces Jitters As Trump Hints At Historic Tariffs, BofA Outlines Probable Timeline ↗
Trump hints at major tariffs on foreign pharmaceuticals, sparking concerns for Indian suppliers and potential hikes in U.S. drug costs. 
Via Benzinga
Topics Government Supply Chain World Trade
News headline image
These S&P500 stocks are gapping in today's session ↗
Stay updated with the S&P500 gap up and gap down stocks on Wednesday. Get a glimpse of the market's movement during today's session. 
Via Chartmill
News headline image
Is Regeneron Pharmaceuticals Gaining or Losing Market Support? ↗
 
Via Benzinga
News headline image
4 Beaten-Down Stocks That Could Skyrocket by 50% to 543%, According to Wall Street ↗
Via The Motley Fool
News headline image
Immuno-Oncology Stocks Q4 Highlights: Incyte (NASDAQ:INCY)
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Incyte (NASDAQ:INCY) and the best and worst... 
Via StockStory
Topics Artificial Intelligence
News headline image
3 Growth Stocks That Have Turned $1,000 Into More Than $100,000 in 20 Years ↗
Via The Motley Fool
News headline image
Vertex, Alnylam Best Positioned As Biopharma Braces For Tariff Impact, Goldman Sachs Flags Regeneron, Biogen Risks ↗
Trump's new tariff move may raise U.S. pharma costs, with analysts warning of risks tied to EU manufacturing and shifting healthcare policies. 
Via Benzinga
Topics Government World Trade
News headline image
In a market where value is scarce, REGENERON PHARMACEUTICALS (NASDAQ:REGN) offers a refreshing opportunity with its solid fundamentals. ↗
Uncover the potential of REGENERON PHARMACEUTICALS, an undervalued stock. NASDAQ:REGN maintains a strong financial position and offers an appealing valuation. 
Via Chartmill
News headline image
Retail Traders Mostly Bullish On Biotech Stocks Amid Blow From RFK Jr. Purge On Health Agencies ↗
The sector's recent slide follows Peter Marks' resignation last week as the Food and Drug Administration's top vaccine regulator following a clash with Kennedy. 
Via Stocktwits
Topics ETFs Government
News headline image
Does AstraZeneca Have 'One Pill To Rule Them All' In Cholesterol? ↗
The company unveiled promising results for its experimental cholesterol treatment, a daily pill that blocks PCSK9. 
Via Investor's Business Daily
News headline image
$1000 Invested In This Stock 20 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
News headline image
Sensei Biotherapeutics Reports Favorable Initial Clinical Activity Data For Solnerstotug In Resistant Tumors ↗
Sensei Biotherapeutics' solnerstotug shows a 14% ORR in PD-(L)1 resistant tumors and remains well tolerated in early trial data from its Phase 1/2 study. 
Via Benzinga
News headline image
Dupixent® (dupilumab) Approved as the First-ever Biologic Medicine in Japan for Patients with Chronic Obstructive Pulmonary Disease (COPD)
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Merck's Biggest Moneymaker Could Get Even Bigger. But Will It Help Downtrodden Shares? ↗
The FDA is due to make an approval decision in mid-September for a key product from the top pharma company. 
Via Investor's Business Daily
News headline image
Why Pharma and Biotech Stocks Got Thrashed on Tuesday ↗
Via The Motley Fool
News headline image
What's going on in today's session: S&P500 movers ↗
Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Tuesday. 
Via Chartmill
News headline image
Regeneron to Report First Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on April 29, 2025
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Unity Biotechnology Unveils Mixed Data From Study For Diabetes-Related Blindness, Stock Falls ↗
Unity diabetes study showing durable vision gains with full 36-week data expected in Q2 2025. 
Via Benzinga
News headline image
Opthea Phase 3 Trial Fails To Meet Primary Endpoint, Faces Financial Uncertainty ↗
Opthea's Phase 3 COAST trial for wet AMD did not meet its primary endpoint, raising financial concerns as the company faces potential investor obligations. 
Via Benzinga
News headline image
3 Reasons to Sell REGN and 1 Stock to Buy Instead
What a brutal six months it’s been for Regeneron. The stock has dropped 39.3% and now trades at $662.80, rattling many shareholders. This might have investors contemplating their next move. 
Via StockStory
News headline image
Natera (NASDAQ:NTRA) Q4 Earnings: Leading The Immuno-Oncology Pack
Wrapping up Q4 earnings, we look at the numbers and key takeaways for the immuno-oncology stocks, including Natera (NASDAQ:NTRA) and its peers. 
Via StockStory
Topics Artificial Intelligence
News headline image
Price Over Earnings Overview: Regeneron Pharmaceuticals ↗
 
Via Benzinga
News headline image
2 Large-Cap Stocks with Solid Fundamentals and 1 to Brush Off
Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence. With such vast footprints, however, finding new areas for growth is much harder than for... 
Via StockStory
News headline image
Friday's session: top gainers and losers in the S&P500 index ↗
Curious about the S&P500 stocks that are in motion on Friday? Join us as we explore the top movers within the S&P500 index during today's session. 
Via Chartmill
News headline image
These S&P500 stocks are gapping in today's session ↗
Looking for opportunities in today's market? Check out the S&P500 gap up and gap down stocks on Friday and stay ahead of the market trends. 
Via Chartmill
News headline image
3 Stocks With Ironclad Balance Sheets for Long-Term Stability
Check out these three stocks with balance sheets that have a case for being among the strongest in the entire stock market. 
Via MarketBeat
Topics Economy Supply Chain
News headline image
What's going on in today's session: S&P500 gap up and gap down stocks ↗
Curious about the market action on Wednesday? Dive into the US markets to explore the gap up and gap down stocks in the S&P500 index during today's session. 
Via Chartmill
News headline image
Regeneron Science Talent Search 2025 Awards More Than $1.8 Million to High School Seniors for Innovative Scientific Research on Classifying Objects in Space, Treating a Rare Muscle Disease and Solving a Long-Standing Math Problem
$250,000 top award goes to Matteo Paz in America’s longest running and most distinguished science and math competition 
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Which S&P500 stocks are moving on Monday? ↗
Curious about the S&P500 stocks that are in motion on Monday? Join us as we explore the top movers within the S&P500 index during today's session. 
Via Chartmill
< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
58 59 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.